Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, has appointed a new member to its medical advisory board. According to the announcement, Mark Gilbert, MD, will be joining the board, bringing board membership to eight. A scientist emeritus at the National Institutes of Health (“NIH”), Gilbert served as chief of the neurooncology branch at NIH for a decade. During that time, Gilbert facilitated a team of laboratory and clinical investigators involved in groundbreaking research that advanced science in the brain tumor field. In addition to his experience at NIH, Gilbert practiced under world-renowned oncologist Dr. Alfred Yung, who is also a member of Calidi’s medical advisory board, MD Anderson in Houston; he also worked at UPMC in Pittsburgh, Emory University in Atlanta and Johns Hopkins in Baltimore. “We are honored that Dr. Gilbert has recognized the revolutionary science at Calidi Biotherapeutics in both tumoral and glioblastoma cancer treatment,” saidCalidi Biotherapeutics CEO Allan Camaisa in the press release. “He joins other luminaries on our medical advisory board who also believe in our stem-cell based therapy’s potential to offer hope and better results for those with cancer. . . . Dr. Gilbert’s expertise and experience will aid in guiding us on developing innovative, multi-institutional studies, partnering with national centers of excellence and key components of the NCI and NIH through Cooperative Research Development Agreements (‘CRADAs’) and other submissions. This will enable us to do some groundbreaking research to help people.”
To view the full press release, visit https://ibn.fm/TJuTU
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. For more information about the company, please visit www.CalidiBio.com.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
